|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-2.61/--
|
Enterprise Value
8.51M
|
Balance Sheet |
Book Value Per Share
1.99
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
8.56K
|
Operating Revenue Per Share
0.00
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/12/24 12:22 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developinga proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. |